Atea Pharmaceuticals Inc., a clinical-stage biotech that specializes in anti-viral therapies, set terms for its initial public offering on Monday with plans to offer 11 million shares priced at $22 to $24 each. The company has applied to list on Nasdaq, under the ticker “AVIR.” J.P. Morgan, Morgan Stanley, Evercore and William Blair are underwriting the deal. Proceeds will be used for clinical trials, R&D and working capital.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.